Skip to main content
Clinical Trials/NCT05389683
NCT05389683
Completed
Not Applicable

Assessment of Improvement in Food Sensitivity Related Symptoms on Employment of Personalized Elimination Diet

Vibrant America Clinical Lab9 sites in 1 country80 target enrollmentStarted: January 2, 2023Last updated:

Overview

Phase
Not Applicable
Status
Completed
Enrollment
80
Locations
9
Primary Endpoint
Improvement in severity of food sensitivity symptoms

Overview

Brief Summary

The goal is to identify food sensitivity in patients and assess whether the avoidance of the reaction-inducing foods via an 'elimination diet' leads to improvement in patient symptoms and overall well-being.

Detailed Description

After seeking appropriate consent, patients' blood samples will be tested for the reactivity toward 262 foods using peptide and protein microarrays. Food protein extraction will be carried out in different solvents such as water and alcohol. The peptide microarrays will synthesize the entire food proteins as peptides in situ while the protein microarrays will test for water-soluble and alcohol-soluble fractions. Thus, food sensitivity testing will be carried out at 3 different levels including water-soluble proteins, alcohol-soluble proteins, and peptides. Patients' blood samples can be tested at all 3 levels or a combination of these. This decision lies at the discretion of the physician.

Based on the test results and as per the physician's recommendations, a suitable elimination diet will be suggested to the patient. Personalized diet suggestions for each patient will be made by the physician. The patient will follow the diet for 4 weeks and blood samples will be tested again on completion of the diet, using peptides and protein microarrays. Additionally, based on the physician's recommendations, the time duration for which a patient follows the personalized elimination diet can be modified.

The patients will periodically have to fill out diagnostic questionnaires which will help assess the changes in their food sensitivity-related symptoms. Changes in the blood biomarkers and improvement in symptoms will be monitored during the study.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients aged between 18 to 65 years.
  • Patients suffering from food sensitivity symptoms
  • Patients having Immunoglobulin G (IgG) and Immunoglobulin A (IgA)-mediated food reactions leading to food sensitivity
  • Patients agreeing to follow the diet per testing
  • Patients willing to provide an informed consent

Exclusion Criteria

  • Patients suffering from chronic medical conditions like cancer
  • Pregnant subjects
  • Patients who have recently used antibiotics
  • Patients who have previously undergone treatments for food allergies/sensitivities
  • Patients who have been assigned an elimination diet before
  • Patients who are already following a restricted diet of any kind
  • Patients unwilling/unable to provide informed consent

Outcomes

Primary Outcomes

Improvement in severity of food sensitivity symptoms

Time Frame: Baseline; Week 1; Week 2; Week 3; Week 4

Food Sensitivity - Symptom Severity Scale (FS - SSS) is a 16-item questionnaire that will assess the severity of the patient's food sensitivity-related symptoms. The scores range from 0 (none) to 5 (severe).

Improvement in blood biomarker profile

Time Frame: Baseline - 4 weeks

The peptide and protein microarrays will be used to test patients' blood samples prior to and post-employment of the elimination diet, and changes in the blood biomarker profile will be monitored. Testing will be carried out at baseline and then after 4 weeks, on completion of the diet.

Secondary Outcomes

  • Food sensitivity - Global Improvement Scale (FS-GIS)(Week 4)
  • Food Sensitivity - Quality of Life Questionnaire (FS-QoL)(Baseline; Week 4)

Investigators

Sponsor Class
Industry
Responsible Party
Principal Investigator
Principal Investigator

Hari Krishnamurthy

Director - Biomedical Engineering

Vibrant America Clinical Lab

Study Sites (9)

Loading locations...

Similar Trials